Major pathologic response as a prognostic surrogate in esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy/chemoimmunotherapy: A multi-center cohort study
MPR can serve as an independent prognostic factor and a surrogate of survival endpoints in ESCC patients undergoing nCT/nICT. Besides, as a potential indicator for postoperative management, MPR can provide reference basis and evidence support in clinical practice.
Authors
- Hui Xu (ORCID: https://orcid.org/0000-0001-5517-3556)
- Zhi-Nuan Hong (ORCID: https://orcid.org/0000-0002-1800-6158)
- Shuhan Xie
- Wenyi Liu (ORCID: https://orcid.org/0000-0002-5921-4674)
- Sunkui Ke
- Shuchen Chen (ORCID: https://orcid.org/0000-0002-3316-9908)
- Shijie Huang (ORCID: https://orcid.org/0000-0002-9508-0458)
- Jinxin Xu (ORCID: https://orcid.org/0000-0001-5399-4633)
- Mingqiang Kang (ORCID: https://orcid.org/0000-0001-5676-5182)
- Jinbiao Xie (ORCID: https://orcid.org/0000-0002-4021-9504)
Institutions
- Fujian Medical University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Zhongshan Hospital of Xiamen University (CN)
- Putian University (CN)
Publication Details
- Journal
- European Journal of Surgical Oncology
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1016/j.ejso.2024.109500
- Citations
- 8
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 4.58
Funders
- National Natural Science Foundation of China
- Fujian Medical University